ANGO Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q2

FY2026Q3

FY2026Q4

76.43M

+4.93%

-0.098

+143.75%

76.70M

+6.52%

-0.090

-400%

81.40M

+1.55%

-0.035

+16.67%

Estimates Revision

The market is revising Upward the revenue expectations for AngioDynamics, Inc. (ANGO) for FY2026, with the revenue forecasts being adjusted by 0.02% over the past three months. During the same period, the stock price has changed by -10.23%.

Revenue Estimates for FY2026

Revise Upward

+0.02%

In Past 3 Month

EPS Estimates for FY2026

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-10.23%

In Past 3 Month

3 Analyst Rating

Wall Street analysts forecast ANGO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANGO is 19.33 USD with a low forecast of 16.00 USD and a high forecast of 24.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

16.00

Averages

19.33

High

24.00

Current: 0.000

Low

16.00

Averages

19.33

High

24.00

Canaccord

John Young

Buy

maintain

$15 -> $17

2025-07-16

Reason

Canaccord

John Young

Price Target

$15 -> $17

2025-07-16

maintain

Buy

Reason

Canaccord analyst John Young raised the firm's price target on AngioDynamics to $17 from $15 and keeps a Buy rating on the shares. The firm said the company had another well-executed quarter, driven by growth in its Med-Tech business with nice beats across the board. Med-Tech, Med-Device, total revenues, adj. EBITDA and adj. EPS all beat estimates, capping off a momentum-building year for the company and there wasn't much thesis changing news for the company during the quarter.

Lake Street

Buy

initiated

$24

2025-07-16

Reason

Lake Street

Price Target

$24

2025-07-16

initiated

Buy

Reason

Lake Street initiated coverage of AngioDynamics with a Buy rating and $24 price target. The firm says the company has transformed its portfolio into faster-growth and higher-margin cardiovascular and cancer treatment products. The Street is missing AngioDynamics' strategic realignment as the shares should be valued more in line with higher multiple medical technology companies, the analyst tells investors in a research note.

HC Wainwright & Co.

Yi Chen

Strong Buy

Maintains

$15 → $16

2025-04-07

Reason

HC Wainwright & Co.

Yi Chen

Price Target

$15 → $16

2025-04-07

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Yi Chen

Strong Buy

Maintains

$14 → $15

2025-01-10

Reason

HC Wainwright & Co.

Yi Chen

Price Target

$14 → $15

2025-01-10

Maintains

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for AngioDynamics Inc (ANGO.O) is -45.83, compared to its 5-year average forward P/E of -108.26. For a more detailed relative valuation and DCF analysis to assess AngioDynamics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-108.26

Current PE

-45.83

Overvalued PE

265.60

Undervalued PE

-482.13

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-6.31

Current EV/EBITDA

65.33

Overvalued EV/EBITDA

179.10

Undervalued EV/EBITDA

-191.71

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

1.78

Current PS

1.66

Overvalued PS

2.63

Undervalued PS

0.92

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ANGO News & Events

Events Timeline

No data

News

2.0

01-06NASDAQ.COM

AngioDynamics (ANGO) Q3 2025 Earnings Transcript

2.0

01-06NASDAQ.COM

AngioDynamics (ANGO) Q1 2026 Earnings Transcript

2.0

01-06NASDAQ.COM

AngioDynamics (ANGO) Q2 2026 Earnings Transcript

People Also Watch

Frequently Asked Questions

What is AngioDynamics Inc (ANGO) stock price today?

The current price of ANGO is 10.0001 USD — it has decreased -0.5 % in the last trading day.

What is AngioDynamics Inc (ANGO)'s business?

AngioDynamics, Inc. is a transformative medical technology company. The Company is focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients. It designs, manufactures, and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Its devices are generally used in minimally invasive, image-guided procedures. Its segments include Med Tech and Med Device. Its product categories include oncology, venous therapies, vascular interventions, and ports. Its oncology products include Model 1500X RF Generator, IsoLoc Endorectal Balloon, Habib 4X Laparoscopic Bipolar Resection Device, Habib 4X Bipolar Resection Device, and Alatus. Its venous therapies include VenaCure EVLT 1470 Pro Laser, VenaCure EVLT System, VenaCure EVLT Procedure Packs, and others.

What is the price predicton of ANGO Stock?

What is AngioDynamics Inc (ANGO)'s revenue for the last quarter?

AngioDynamics Inc revenue for the last quarter amounts to 79.43M USD, increased 9.04 % YoY.

What is AngioDynamics Inc (ANGO)'s earnings per share (EPS) for the last quarter?

AngioDynamics Inc. EPS for the last quarter amounts to -0.15 USD, decreased -42.31 % YoY.

What changes have occurred in the market's expectations for AngioDynamics Inc (ANGO)'s fundamentals?

How many employees does AngioDynamics Inc (ANGO). have?

AngioDynamics Inc (ANGO) has 675 emplpoyees as of January 09 2026.

What is AngioDynamics Inc (ANGO) market cap?

Today ANGO has the market capitalization of 414.23M USD.